Amazed you found the BiogenIdec so fast, as I was just getting around to post it.

So now there can be no disagreement about the postmarketing numbers of patients on Tysabri. I still firmly believe that you cannot mix the post marketing PML cases (4) with the pre marketing PML cases (3) because of the changes implemented for commercial use - wash-outs, montherapy, TOUCH program in the US.

As far as additional "possible" PML cases, remember BiogenIdec just informed us that there were no additional cases as of 1/09/08.